Vycor Medical, Inc. (OTCQB: $VYCO) reported results for the year ended December 31, 2024, with full-year revenues of $1.59 million, a 9% increase over 2023. The Vycor Medical division, which produces the FDA-cleared ViewSite™ Brain Access System (VBAS), accounted for all of the

#DeltaSurgical are attending the 29th ESPN Congress #ESPN2025 next week, bringing a variety of paediatric #neurosurgical devices inc the Black Forest Medical Group Lucent Pro Paediatric Headrest Vycor Medical, Inc. VBAS tubular retractors #Rowena neurosurgical training simulator. See you there!

Vycor Medical, Inc. (OTCQB: VYCO) announced financial results for the three months ended March 31, 2025, reporting 31% year-over-year growth in Vycor Medical division revenue alongside strategic progress in expanding its global footprint. Vycor Medical, Inc. (OTCQB: VYCO) is a

Vycor Medical, Inc. Vycor Medical’s continued growth reflects both strategic execution and clinical innovation. To explore the company’s full profile—including recent financials, product insights, and global expansion—visit the Featured Venture Company section of the B2i Digital website.

In brain surgery, the less disruption to healthy tissue, the better. That’s why neurosurgeons increasingly favor techniques and tools that allow them to reach deep-seated brain lesions without causing unnecessary harm. With the goal of designing a minimally invasive device to

Explore Vycor Medical’s full profile at b2idigital.com/vycor-medical to learn how the company is advancing minimally invasive neurosurgery and neuro-rehabilitation. Discover the impact of VBAS and NovaVision® in improving outcomes for patients and surgeons alike.

When it comes to brain surgery, even the steadiest hands can’t guarantee successful outcomes. Once the surgeon reaches a tumor or blood clot, the objective is not only to remove the pathology but also to avoid damaging healthy tissue that can affect memory, movement, or speech.

In brain surgery, the less disruption to healthy tissue, the better. That’s why neurosurgeons increasingly favor techniques and tools that allow them to reach deep-seated brain lesions without causing unnecessary harm. With the goal of designing a minimally invasive device to

Pediatric neurosurgery presents unique challenges, the most notable of which is the need to access smaller anatomical structures. Vycor Medical’s ViewSite™ Brain Access System (VBAS) has demonstrated particular success in pediatric applications, with several peer-reviewed

Vycor Medical, Inc. David Shapiro - CEO of B2i Digital, Inc. Vycor Medical’s innovations in pediatric neurosurgery continue to gain clinical validation. To explore more about their groundbreaking technologies, including the ViewSite™ Brain Access System (VBAS) and NovaVision® platform, visit their full profile at b2idigital.com/vycor-medical.

For neurosurgeons, visibility matters. With that in mind, Vycor Medical designed the ViewSite™ Brain Access System (VBAS) to be fully transparent, enabling surgeons to maintain a direct view of the surgical field while gently displacing brain tissue during complex procedures.

When it comes to brain surgery, even the steadiest hands can’t guarantee successful outcomes. Once the surgeon reaches a tumor or blood clot, the objective is not only to remove the pathology but also to avoid damaging healthy tissue that can affect memory, movement, or speech.

Brain surgery requires a delicate balance: accessing deep lesions while preserving the key parts of the brain that control movement, speech, and memory. Research indicates that the type of retractor used during surgery can significantly impact this balance, with newer tubular

The VBAS Alignment Clip combines with the #VBAS #BrainRetraction device Vycor Medical, Inc., allowing its use with neuro-navigation & aligns the #IGS pointer along the central vertical axis of the introducer helping prevent sideways movement of the pointer. #DeltaSurgical 01782 637009

Vycor Medical, Inc. (OTCQB: VYCO) announced the publication of a new peer-reviewed clinical study on its NovaVision division’s NeuroEyeCoach training program, demonstrating significant benefits for stroke patients recovering from visual disorders in both home and clinic settings.

Pediatric neurosurgery presents unique challenges, the most notable of which is the need to access smaller anatomical structures. Vycor Medical’s ViewSite™ Brain Access System (VBAS) has demonstrated particular success in pediatric applications, with several peer-reviewed

New Insights from Vycor Medical, Inc. (OTCQB: VYCO) on Restoring Vision After Stroke Just published an article exploring how NeuroEyeCoach, a clinically validated and FDA-registered therapy from NovaVision, is helping stroke survivors with visual field loss regain functional

New Insights from Vycor Medical, Inc. (OTCQB: VYCO) on Advancing Minimally Invasive Brain Surgery Vycor Medical, Inc. is a B2i Digital Featured Venture Company. See the complete profile at b2idigital.com/vycor-medical A recent clinical study highlights how tubular

Vycor Medical’s ViewSite™ Brain Access System (VBAS) is reshaping recovery trajectories in neurosurgery by shortening OR time and accelerating the transition from the OR to home. By minimizing retractor-related brain injury, VBAS enables shorter hospital stays, faster

Vycor Medical is helping to transform neurosurgical outcomes with its ViewSite™ Brain Access System (VBAS), a tubular retractor that enables surgeons to access deep brain lesions while minimizing tissue trauma. In a new article published on LinkedIn, Vycor examines the growing